Study Title

A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

Study Details

Description:

This is a first-in-human Phase 1 clinical trial designed to investigate the safety, tolerability, pharmacokinetics, and biodistribution of [225Ac]-FPI-2059 and [111In]-FPI-2058 in participants with neurotensin receptor 1 (NTSR1)-expressing solid tumours.

Sponsor:

Fusion Pharmaceuticals, Inc.

Contacts:

Clinical Trials

clinicaltrials@fusionpharma.com

1 (888) 506-4215

Government Study Link:

NCT05605522 - Click here to see study on

ClinicalTrials.gov

Inclusion

Histologically or cytologically confirmed solid tumor prostrate metastatically/locally advamced PDAC CRC,NED
disease that has progressed despite prior treatment and for which additional effective standard therapy is not available
sufficient target expression at least 1 measurable lesion finding by Imaging following injection of In-FPI-2058
Measurable disease per RECIST v1.1
Tumor tissue(either archival within last 24 month or fresh biopsy

Exclusion

Exclusion Criteria Not Yet Provided

Patient Education

Patient Education Not Yet Provided

Publications

NTSR1-Targeted Alpha Therapeutic [225Ac]-FPI-2059 Induces Growth Inhibition In A Preclinical Colorectal Tumor Model

Locations

United States

XCancer - Omaha

17607 Gold Plaza, Omaha, Nebraska 68130, United States

This badge indicates the Principal Investigator has a proven record of excellence in the advancement of Theranostics.